A clearer understanding of the Inflation Reduction Act’s implications is needed for manufacturers to plot a successful course forward....

The quality of the clinical evidence will forever be the cornerstone of every payer engagement. Poor integration of payer insights into...

Formulary Insights transformed the payer market research landscape providing a better way to capture and deliver accurate payer insights.

Following a year which saw a 143% increase in launched biosimilars in the US, three reasons why payers will drive adoption further in 2021.

Payers have transformed the competitive marketplace, and biopharma companies need to regain their role as the authority on their products.

As payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.